INmune Bio
INMB
34 hedge funds and large institutions have $19.1M invested in INmune Bio in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 10 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
1.08% less ownership
Funds ownership: 13.94% → 12.86% (-1.1%)
16% less call options, than puts
Call options by funds: $300K | Put options by funds: $356K
21% less funds holding
Funds holding: 43 → 34 (-9)
24% less capital invested
Capital invested by funds: $25.3M → $19.1M (-$6.17M)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$1.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$383K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$187K |
| 4 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$167K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$89.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.54M |
| 2 |
Morgan Stanley
New York
|
-$701K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$372K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$346K |
| 5 |
VF
Virtu Financial
New York
|
-$249K |
INMB Hedge Fund Activity: Q1 2022 in Review
34 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2022, worth a combined $19.1M — down 24% from $25.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INMB and 1 opened new positions — a net loss of 9 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Janney Montgomery Scott, adding an estimated $1.32M. The largest seller was Millennium Management, exiting entirely with an estimated $1.54M sold.
- 34 institutional investors held INmune Bio (INMB) as of Q1 2022, down from 43 in Q4 2021.
- Funds reported $19.1M of INmune Bio stock for Q1 2022, down 24% quarter-over-quarter.
- 1 fund opened new INmune Bio positions in Q1 2022 and 10 closed out, a net change of -9 holders.
- The largest INmune Bio buyer in Q1 2022 was Janney Montgomery Scott, an estimated $1.32M added.
- The largest INmune Bio seller in Q1 2022 was Millennium Management, an estimated $1.54M sold.
Based on aggregated 13F filings for Q1 2022.